AdaptHealth, the Healthcare sector company, was revisited by a Wall Street analyst on August 13. Analyst Whit Mayo from Leerink Partners reiterated a Buy rating on the stock and has a $13.00 price target.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Whit Mayo has given his Buy rating due to a combination of factors that highlight AdaptHealth’s positive trajectory. The company’s second-quarter results were promising, with diabetes management showing signs of recovery and sleep-related issues being addressed effectively. The announcement of a new national health system contract further strengthens AdaptHealth’s position, offering a significant revenue boost and expanding their capitated business.
Additionally, AdaptHealth’s cash flow remains robust, with expectations of reduced net leverage by year-end. Despite a slight reduction in EBITDA forecasts for the coming years, the company’s valuation remains attractive. The ongoing operational improvements and strategic initiatives across various business lines, such as respiratory and sleep, contribute to a positive outlook, supporting the Buy rating.
In another report released on August 13, Canaccord Genuity also maintained a Buy rating on the stock with a $14.00 price target.